Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Berberine101 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00413 | 35093393 | Biochem Pharmacol | Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease. | 2022 | Details |
| A00797 | 34964117 | Compr Physiol | Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. | 2021 | Details |
| A00850 | 34948230 | Int J Mol Sci | It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? | 2021 | Details |
| A00869 | 34944525 | Biomolecules | A System-Level Mechanism of Anmyungambi Decoction for Obesity: A Network Pharmacological Approach. | 2021 | Details |
| A01579 | 34686466 | J Integr Med | Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. | 2021 | Details |
| A01605 | 34681219 | Pharmaceuticals (Basel) | Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. | 2021 | Details |
| A01902 | 34566663 | Front Pharmacol | Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies. | 2021 | Details |
| A01996 | 34535644 | Nat Commun | A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. | 2021 | Details |
| A02108 | 34504563 | Exp Ther Med | Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR. | 2021 | Details |
| A02306 | 34426744 | Evid Based Complement Alternat Med | Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver. | 2021 | Details |
| A02474 | 34360538 | Int J Mol Sci | Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. | 2021 | Details |
| A02506 | 34348707 | J Nanobiotechnology | Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. | 2021 | Details |
| A02932 | 34192596 | Life Sci | Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice. | 2021 | Details |
| A03195 | 34094026 | Iran J Basic Med Sci | The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. | 2021 | Details |
| A03296 | 34056769 | Phytother Res | Molecular updates on berberine in liver diseases: Bench to bedside. | 2021 | Details |
| A03453 | 33994854 | Int J Biol Sci | Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. | 2021 | Details |
| A03460 | 33992930 | Eur J Med Chem | Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview. | 2021 | Details |
| A03630 | 33924725 | Nutrients | The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. | 2021 | Details |
| A03796 | 33861449 | Adv Exp Med Biol | Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A03797 | 33861444 | Adv Exp Med Biol | Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review. | 2021 | Details |
| A03846 | 33849107 | Ann Palliat Med | Qinghua Fang inhibits high-fat diet-induced non-alcoholic fatty liver disease by modulating gut microbiota. | 2021 | Details |
| A03891 | 33831691 | Phytomedicine | Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. | 2021 | Details |
| A03915 | 33820503 | Mini Rev Med Chem | Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A04419 | 33626003 | Turk J Gastroenterol | Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway. | 2020 | Details |
| A04820 | 33494295 | Cells | Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. | 2021 | Details |
| A05040 | 33397443 | Biol Sex Differ | Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. | 2021 | Details |
| A05617 | 33186794 | Biomed Pharmacother | Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. | 2020 | Details |
| A05695 | 33152943 | Biomed Pharmacother | The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. | 2020 | Details |
| A07367 | 32524150 | Naunyn Schmiedebergs Arch Pharmacol | Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio. | 2020 | Details |
| A07597 | 32429849 | BMC Immunol | Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. | 2020 | Details |
| A07666 | 32403887 | Zhonghua Gan Zang Bing Za Zhi | [Discussion on the curative effect and mechanisms of berberine in rats with non-alcoholic fatty liver]. | 2020 | Details |
| A07778 | 32357187 | PLoS One | Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. | 2020 | Details |
| A08059 | 32265720 | Front Pharmacol | The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism. | 2020 | Details |
| A08222 | 32194416 | Front Pharmacol | Berberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis via the ROS/TXNIP Axis. | 2020 | Details |
| A08258 | 32184858 | Iran J Pharm Res | In-vitro Synergistic Effect of Metformin and Berberine on High Glucose-induced Lipogenesis. | 2019 | Details |
| A08595 | 32045667 | Pharmacol Res | Human antigen R: A potential therapeutic target for liver diseases. | 2020 | Details |
| A08765 | 31993304 | Acta Pharm Sin B | Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. | 2019 | Details |
| A08837 | 31969822 | Front Pharmacol | Microarray Expression Profiling and Raman Spectroscopy Reveal Anti-Fatty Liver Action of Berberine in a Diet-Induced Larval Zebrafish Model. | 2020 | Details |
| A10712 | 31226399 | Free Radic Biol Med | Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. | 2019 | Details |
| A10732 | 31217846 | Am J Transl Res | Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice. | 2019 | Details |
| A10779 | 31197160 | Cell Death Dis | Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. | 2019 | Details |
| A11504 | 30868489 | Curr Med Sci | Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. | 2019 | Details |
| A11507 | 30867696 | Exp Ther Med | Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway. | 2019 | Details |
| A11548 | 30848932 | FASEB J | Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. | 2019 | Details |
| A11580 | 30832407 | Nutrients | Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function. | 2019 | Details |
| A12929 | 30221732 | Mol Med Rep | Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling. | 2018 | Details |
| A13089 | 30142943 | Nutrients | Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. | 2018 | Details |
| A14250 | 29505790 | Biochem Biophys Res Commun | Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway. | 2018 | Details |
| A14295 | 29477657 | Eur J Pharmacol | Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway. | 2018 | Details |
| A14563 | 29353208 | Biomed Pharmacother | Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. | 2018 | Details |
| A14865 | 29200733 | Pharmacogn Mag | Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats. | 2017 | Details |
| A15410 | 28925892 | Curr Pharm Des | Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A15453 | 28900305 | Sci Rep | Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. | 2017 | Details |
| A16432 | 28393690 | Curr Med Chem | Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products. | 2018 | Details |
| A16560 | 28317281 | Mol Nutr Food Res | Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. | 2017 | Details |
| A16691 | 28241817 | BMC Endocr Disord | Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. | 2017 | Details |
| A17024 | 28038998 | Toxicol Appl Pharmacol | Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. | 2016 | Details |
| A17529 | 27658958 | J Mol Endocrinol | ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. | 2016 | Details |
| A17540 | 27754444 | Molecules | The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A17736 | 27629750 | J Transl Med | Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. | 2016 | Details |
| A17970 | 27446224 | Evid Based Complement Alternat Med | The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. | 2016 | Details |
| A18755 | 26970305 | Biochem Biophys Res Commun | Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. | 2016 | Details |
| A18795 | 26936230 | Sci Rep | Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. | 2016 | Details |
| A18817 | 26923892 | Arch Iran Med | Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. | 2016 | Details |
| A18880 | 26889237 | Exp Ther Med | Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. | 2015 | Details |
| A18943 | 26857750 | Sci Rep | Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. | 2016 | Details |
| A19942 | 26252777 | PLoS One | Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. | 2015 | Details |
| A19981 | 26228038 | Lipids Health Dis | Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. | 2015 | Details |
| A19990 | 26221297 | Int J Clin Exp Med | Berberine reverses abnormal expression of L-type pyruvate kinase by DNA demethylation and histone acetylation in the livers of the non-alcoholic fatty disease rat. | 2015 | Details |
| A20454 | 25951637 | Zhongguo Zhong Xi Yi Jie He Za Zhi | [Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet]. | 2015 | Details |
| A20947 | 25623289 | J Transl Med | Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. | 2015 | Details |
| A23098 | 24041461 | Mitochondrion | Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation. | 2013 | Details |
| A23359 | 23843872 | Evid Based Complement Alternat Med | Update on berberine in nonalcoholic Fatty liver disease. | 2013 | Details |
| A24959 | 22311412 | Chin J Integr Med | Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. | 2012 | Details |
| A24962 | 22308697 | Zhongguo Zhong Yao Za Zhi | [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. | 2011 | Details |
| A25440 | 21839075 | Eur J Pharmacol | Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. | 2011 | Details |
| A25880 | 21359922 | Chin J Integr Med | Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. | 2011 | Details |
| A26377 | 20567026 | J Lipid Res | Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. | 2010 | Details |
| A29086 | 34603061 | Front Pharmacol | Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. | 2021 | Details |
| A32163 | 29075339 | Exp Ther Med | Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice. | 2017 | Details |
| A33163 | 26576191 | Evid Based Complement Alternat Med | Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats. | 2015 | Details |
| A33443 | 25977701 | Evid Based Complement Alternat Med | Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis. | 2015 | Details |
| A42518 | 34305616 | Front Pharmacol | Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota. | 2021 | Details |
| A42975 | 32914727 | Endocr Metab Immune Disord Drug Targets | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. | 2021 | Details |
| A43194 | 32335802 | Front Med | Biological properties and clinical applications of berberine. | 2020 | Details |
| A43790 | 30879091 | Cell Mol Life Sci | Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases. | 2019 | Details |
| A44500 | 28459766 | Curr Opin Lipidol | Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications? | 2017 | Details |
| A45045 | 26308759 | Altern Ther Health Med | Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health. | 2015 | Details |
| A47129 | 25455889 | Food Chem Toxicol | Berberine protects liver from ethanol-induced oxidative stress and steatosis in mice. | 2014 | Details |
| A47134 | 25362106 | J Pharmacol Exp Ther | Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. | 2014 | Details |
| A48828 | 27439970 | Clin Sci (Lond) | NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling. | 2016 | Details |
| A49245 | 35811658 | Dis Markers | Pharmacological Mechanism of Ganlu Powder in the Treatment of NASH Based on Network Pharmacology and Molecular Docking. | 2022 | Details |
| A49459 | 35744831 | Molecules | Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. | 2022 | Details |
| A49524 | 35726797 | Food Funct | Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. | 2022 | Details |
| A49953 | 35584453 | Braz J Med Biol Res | The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. | 2022 | Details |
| A50310 | 35436630 | Biochem Biophys Res Commun | Hydrochloride Berberine ameliorates alcohol-induced liver injury by regulating inflammation and lipid metabolism. | 2022 | Details |
| A50461 | 35382695 | Postgrad Med | Effect of berberine and bicyclol on Chinese patients with nonalcoholic fatty liver disease: a retrospective study. | 2022 | Details |
| A51359 | 35308208 | Front Pharmacol | Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora. | 2022 | Details |